RxDoctor Payments Data

Gregory Gibson, MD

Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1831536747

Payments from drug & device makers

$2,792in general payments, 2019–2025

Across 61 payments — averaging $45.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boehringer Ingelheim$349
  • Pfizer$207
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$152
  • Actelion Pharmaceuticals US, Inc.$149
  • Impulse Dynamics (USA) Inc.$145
  • plus $735 from 11 others

What the payments were for

  • Food & beverage$2,792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,792 in reported general payments places this provider in the 20th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$81,881
Medicare patients
183
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$83,816
EntrestoSacubitril/Valsartan68$76,398
JardianceEmpagliflozin37$38,086
Tadalafil14$21,062
FarxigaDapagliflozin Propanediol22$18,345
Mycophenolate Mofetil24$5,383
Valsartan52$2,053
Metoprolol Succinate129$1,707
Atorvastatin Calcium123$1,410
Torsemide57$1,309
Nitroglycerin15$1,277
Tacrolimus15$1,265
Gabapentin28$1,026
Bumetanide20$991
Doxazosin Mesylate11$970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$207$83,81670 claims
NovartisEntresto$64$76,39868 claims
Boehringer IngelheimJardiance$349$38,08637 claims
AstraZenecaFarxiga$59$18,34522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →